Những podcast Spectives hay nhất (2024)

1
Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC 12:50

17h ago12:50

12:50

When it comes to the treatment of EGFR-mutated metastatic non-small cell lung cancer (NSCLC), osimertinib (Tagrisso) is an “old friend,” says Kamya Sankar, MD, assistant professor and co–medical director of the Thoracic Disease Research Group at Cedars-Sinai Cancer Center in Los Angeles. Recent approvals by the U.S. Food and Drug Administration hav…

1
rivatization of Cancer Clinical Research Raises Concerns for Practice 13:09

5d ago13:09

13:09

“Cancer clinical research has been largely privatized,” explains Joseph Unger, PhD, MS, associate professor in the cancer prevention program at the Fred Hutchinson Cancer Center in Seattle. Dr. Unger and colleagues recently assessed patient enrollment in industry-sponsored and federally sponsored clinical trials. They found an 8:1 ratio favoring pa…

1
What 3 Big Trials Mean for Breast Cancer Practice 12:48

12d ago12:48

12:48

Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from three key studies. Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, explains how findings from the KEYNOTE-756, monarchE, and NATALEE clinica…

1
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer 14:02

19d ago14:02

14:02

Approvals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing for all of us,” explains Ian Krop, MD, PhD, director of the clinical trials office, chief clinical research officer, and associate director for clinica…

1
"Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer 11:00

1M ago11:00

11:00

Newly approved targeted therapies for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are changing care. “We have an abundance of opportunities, but challenges with having to choose the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the …

1
S2 Ep16: Patient, Provider, & Caregiver Connection: Individualizing Care in Hemophilia A to Optimize Joint Health and Prevent Synovitis 40:44

2M ago40:44

40:44

Bởi PER® Spectives

1
E124: Crysis 1:15:50

2M ago1:15:50

1:15:50

But can it run Crysis? This was the motto that surrounded every single PC build for literal years after the release of the game in 2007. Crytek were not satisfied with what they had achieved with Far Cry in 2004, and decided to push graphical hardware to its absolute limits with their brand new and shiny game. And boy, did they succeed, with a poor…

1
After Practice Change in Unresectable Stage III NSCLC, Questions Remain 10:30

2M ago10:30

10:30

Data on the use of durvalumab after chemoradiotherapy transformed the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). “This is a real practice-changing observation from the PACIFIC trial,” said Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Cent…

1
What "Incredibly Dramatic" Data on Osimertinib in NSCLC Mean for Practice 9:47

2M ago9:47

9:47

Results of the phase 3 LAURA clinical trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting, showed that osimertinib significantly improves progression-free survival in patients with unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC) after chemoradiotherapy. “The benefits of osimertinib in this patient…

1
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates 10:08

3M ago10:08

10:08

“I think the antibody-drug conjugates (ADCs) for physicians, and certainly patients too, are a little bit tough to wrap your head around,” says Erika P. Hamilton, MD, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses how TROP2-targeting ADCs currently fit into practice with …

1
Oncology Must Do More for Long-Term Cancer Survivors, Expert Says 11:27

3M ago11:27

11:27

Various survivorship guidelines for pediatric patients have been established, but “such guidelines do not exist in the adult world,” says Smita Bhatia, MD, MPH, director of the Institute for Cancer Outcomes and Survivorship and the Gay and Bew White Endowed Professor in Pediatric Oncology at the University of Alabama at Birmingham. With the number …

1
“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue” 12:00

3M ago12:00

12:00

Obstacles to “achieving a good, peaceful death” prevent many patients with cancer from the “dignified end” that they deserve, says Sunita Puri, MD, a palliative care physician and author. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss frustrations and …

1
E123: Resident Evil 2 1:08:35

3M ago1:08:35

1:08:35

After their magnum opus that was Resident Evil 1, Capcom were not going to sit on their heels. Coming out just two years after the first in 1998, Resident Evil 2 sought to have everything the original had and much, much more. It connected its two character’s stories in far more meaningful ways, increased the size of each player's inventory (and the…

1
FDA Approvals in Relapsed/Refractory CLL Set up "Difficult Choice" 9:59

4M ago9:59

9:59

When it comes to the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), "within the last eight months or so, we have had some exciting new events," says Daniel A. Ermann, MD, a hematologist-oncologist and assistant professor at the University of Utah Huntsman Cancer Institute in Salt Lake City. The U.S. Food and Drug…

1
Oncologists Struggling With Cancer Deaths Among Millennial Patients 11:36

4M ago11:36

11:36

Oncologists are struggling with the rising cancer mortality rate among millennial patients. "I think treating people our own age is definitely a trigger for a lot of people," said Sunita Puri, MD, a palliative-care physician and author. She spoke with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai…

1
Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree 12:23

4M ago12:23

12:23

Thoracic oncology was a major focus of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, says Sandip P. Patel, MD, a medical oncologist and professor of medicine at the University of California San Diego. Practice-changing data were presented in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), Dr. Patel…

1
E122: The Legend of Zelda 1:09:44

4M ago1:09:44

1:09:44

The Legend of Zelda is perhaps the most iconic video game series of all time. Boasting 19 mainline entries, and an endless swathe of critical acclaim and awards, it's hard to find someone who hasn’t at least heard of the action/adventure story of Link and Zelda. It all began back in 1986 with the release of the first game for the Famicom in Japan. …

1
What Were the Biggest Data at ASCO 2024 in Kidney Cancer? 11:41

4M ago11:41

11:41

The biggest data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in kidney cancer focused on biomarkers, says Brian I. Rini, MD, chief of clinical trials and the Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center in Nashville. He discussed data from KEYNOTE-426 and several other key trials with Robert…

1
What New “Elephant in the Room” Means for Bladder Cancer Care 14:00

4M ago14:00

14:00

Enfortumab vedotin plus pembrolizumab (EV/pembro) has “become the elephant in the room” when it comes to bladder cancer care, says Jonathan E. Rosenberg, MD, chief of genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. At the 2024 American Society of Clinical Oncology Annual Meeting, he discussed recent key ad…

1
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice 12:08

4M ago12:08

12:08

Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice Our host, Robert A. Figlin, MD, FACP, welcomes Melissa L. Johnson, MD, as a guest

1
"We're Past the Inflection Point," as "Massive Change" Hits Breast Cancer Care 13:54

4M ago13:54

13:54

From ASCO 2024. When it comes to the use of antibody-drug conjugates (ADCs) in breast cancer care, "we're past the inflection point," says Hope S. Rugo, MD, a breast cancer oncologist and professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.…

1
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA"? 13:06

5M ago13:06

13:06

From ASCO 2024 The time it takes for a novel cancer therapy to go from investigational new drug application to U.S. Food and Drug Administration (FDA) approval is typically longer than a decade. “There has to be a better way,” says Bob T. Li, MD, PhD, MPH, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City and associate…

1
E121: Killer 7 2:20:23

5M ago2:20:23

2:20:23

Killer7 is one weird game. Developed in tandem by Grasshopper Manufacture and Capcom and first released in 2005, its very existence as a game defies description. Within moments of starting, you’re placed into a world with talking bondage ghosts, a TV channel that drains your blood, and abstract puzzles that would fit right into Resident Evil. Combi…

1
"Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More 12:32

5M ago12:32

12:32

From ASCO 2024, Dr. Robert Figlin speaks with Dr. Samer Al Hadadi from University of Arkansas. "Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More.

1
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected" 10:29

5M ago10:29

10:29

From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center. Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"

1
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says 25:13

5M ago25:13

25:13

From ASCO 2024 New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says. Dr. Robert Figlin speaks with Dr. Christian Blank from Leiden University

1
Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That" 10:46

5M ago10:46

10:46

From ASCO 2024, Dr. Robert Figlin welcomes Dr. Aditya Bardia from UCLA Health Jonsson Comprehensive Cancer Center. Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"

1
E120: System Shock 2 1:55:24

5M ago1:55:24

1:55:24

System Shock 2 is considered by many to be the finest immersive sim ever made. Released in 1999 in a coventure by Looking Glass Studios and Irrational Games, it sought to combine the classic 3D dungeon crawling of the original with pen and paper inspired RPG systems. While resource management and exploration were still a key part of the experience,…

1
Oncologist Shortage “Has Gotten to the Crisis Level” 10:02

6M ago10:02

10:02

Especially in rural areas, the growing oncologist shortage has “gotten to crisis level,” says Harsha Vyas, MD, president and founding partner of Cancer Center of Middle Georgia in Dublin. “We just don’t have enough supply of medical oncologists/hematologists,” he tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology a…

1
E119: Gran Turismo 4 1:33:36

6M ago1:33:36

1:33:36

Over the years, we’ve played games from pretty much every genre under the sun, but there is one that is notably missing - the racing sim. We’ve dabbled with arcade racers like Burnout 3, and have played several kart racers - Diddy Kong and F-Zero GX to name a couple. But this is the first time we’re trying to learn how to actually drive a racing ca…

1
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use 9:20

7M ago9:20

9:20

The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A. Figlin, MD, the Steven Spiel…

1
Episode 118: Hitman Bloodmoney 1:39:05

7M ago1:39:05

1:39:05

Hitman: Blood Money, first released in 2006 by Eidos, is considered by many to be the best Hitman game ever made. After the first few games played around with novel ideas and concepts to mixed success, Blood Money honed in on the formulae of specific, small and dense environments filled with ‘accidental’ scripted opportunities to murder your target…

1
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care 11:01

7M ago11:01

11:01

Given recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and when should chemotherapy be introduced? “It’s better to have choices than not,” explains Paul Bunn, MD, the Dudley Chair in Cancer Research at the University of Colorado in Aurora. Dr. Bunn discuss…

1
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer 11:16

8M ago11:16

11:16

The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. Data from the recent EMBARK trial have changed practice for…

1
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming” 11:26

8M ago11:26

11:26

The U.S. Food and Drug Administration’s recent accelerated approval of a tumor-infiltrating lymphocyte therapy in metastatic melanoma “is a real milestone,” after the approach was “pending for decades,” explains Jeffrey S. Weber, MD, PhD, deputy director at the NYU Langone Perlmutter Cancer Center. Dr. Weber, who was part of the team to first work …

1
Episode 117: Final Fantasy VII 2:43:07

8M ago2:43:07

2:43:07

Final Fantasy VII is a landmark title not only for the JRPG genre, but for all video games. First released in 1997 and developed by Square, it took the format of the previous games and brought them to life with 3D models and environments. Featuring an ambitious and creative setting, a complicated plot with intrigue and a seemingly deep and engaging…

1
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care 10:48

8M ago10:48

10:48

Recent advances in metastatic urothelial carcinoma have meant that optimistic outcomes are “not as much of a fairytale,” says Robert Dreicer, MD, deputy director of the UVA Cancer Center and professor of medicine and urology at the University of Virginia School of Medicine in Charlottesville. From the recent approval of enfortumab vedotin plus pemb…

1
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression 11:57

9M ago11:57

11:57

Recent approvals by the U.S. Food and Drug Administration (FDA) and findings from pivotal clinical trials have changed care for patients with breast cancer that has progressed after frontline hormone therapy. Ruth M. O’Regan, MD, chair of medicine and Charles H. Dewey Professor at the University of Rochester in New York, highlights which recent dev…

1
Controversies, Difficult Questions Arise in NSCLC Amid New Data 11:22

9M ago11:22

11:22

Recent data on the use of immunotherapy and targeted treatments in patients with advanced non-small cell lung cancer (NSCLC) have introduced a myriad of questions. These include controversial topics and difficult decisions, like when to incorporate CTLA-4 inhibition and what patients can expect from immuno-oncology monotherapy in the metastatic set…

1
What FDA Approval of Belzutifan Means for Kidney Cancer Care 10:08

9M ago10:08

10:08

Belzutifan was recently approved by the U.S. Food and Drug Administration (FDA) for use in previously treated adults with advanced renal cell carcinoma. How should this drug best be incorporated into practice? Eric Jonasch, MD, professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Hous…

1
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer 12:04

9M ago12:04

12:04

CDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug development and section head for endocrine therapy research at Memorial Sloan Kettering in New York City. However, optimal treatment strategies have been complicated by a lack of head-to-head trials. Dr. …

1
S2 Ep15: PER®Spectives: Advancing Treatment in nAMD and DME with Novel Therapies 18:11

9M ago18:11

18:11

This PER®Spectives™ podcast examines opportunities for extended treatment intervals associated with newer therapies for patients with neovascular age-related macular degeneration or diabetic macular edema. In this podcast, experts Arshad Khanani, MD, Ferhina Ali, MD, and Michael Singer, MD, offer real-world data and personal insights into the use o…

Podcast đáng để nghe

Podcast Spectives

Podcast đáng để nghe

Hướng dẫn sử dụng nhanh